ANGPTL3 and familial hypercholesterolemia: Evinacumab, a monoclonal antibody described as an anti-ANGPTL3 antibody approved for treatment of homozygous familial hypercholesterolemia, was recently shown to be a more potent inhibitor of ANGPTL3/8 than of ANGPTL329.